STUDY PERIOD | |||||
---|---|---|---|---|---|
Enrolment | First Visit | Subsequent Visit | End of Treatment | End of Study | |
V1 | Vx | ||||
Informed consent | x | ||||
Inclusion/exclusion criteria | x | ||||
Cohort allocation (sunitinib/pazopanib group) | x | ||||
Socio-demographic data | x | ||||
Renal cell carcinoma history | x | ||||
Prior medication review | x | ||||
CHES software training | x | ||||
Delivery of passwords, username and leaflet | x | ||||
Level of experience with computer tools | x | ||||
Full physical examination | x | x | x | x | |
Karnofsky index | x | x | x | x | |
Adverse events monitoring (NCI CTCAE V4) | x | x | x | x | |
TKI prescription/dose adaptation | x | x | x | x | |
Concomitant medications | x | x | x | x | |
Supportive care prescription | x | x | x | ||
Electronic questionnaire EORTC QLQ-C30 + 9 items EORTC Library Item | x | x | x | ||
Electronic questionnaire EuroQoL EQ-5D-5L | x | x | x | ||
Need help to fill out questionnaires | x | x | x | ||
Location (home or hospital) where the patient completes the questionnaire | x | x | x | ||
Measure of time to fill the questionnaires | x | x | x | ||
Progression and subsequent anti-cancer treatment if applicable | x | x | x | ||
Survival status | x | x | x | x | |
Satisfaction physician questionnaire | x | ||||
Satisfaction research assistant questionnaire | x |